HK Stock Movement | HANSOH PHARMA (03692) Rises Over 4% Before Noon; Ameile® Gains Fifth Indication Approval; Adjuvant Therapy Research Published in The Lancet Oncology

Stock News01-13

HANSOH PHARMA (03692) rose more than 4% before noon. As of the time of writing, the stock was up 3.64%, trading at HK$42.12 with a turnover of HK$97.6223 million. On January 8, HANSOH PHARMA announced that its innovative drug Ameile® (Aumolertinib Mesilate Tablets) received a drug registration certificate from the National Medical Products Administration (NMPA) of China, approving the addition of a new indication. The new indication is for the first-line treatment of Ameile® in combination with pemetrexed and platinum-based chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations. This marks the fifth indication approved for Ameile®. Notably, according to a post on HANSOH PHARMA's official WeChat account, the latest research results for the company's innovative drug Ameile® (Aumolertinib Mesilate Tablets, 110mg) used as adjuvant therapy for EGFR-mutated NSCLC were recently published online in the prestigious international oncology journal *The Lancet Oncology* (Impact Factor: 35.9). The data showed that Ameile® significantly improved disease-free survival (DFS) in patients with completely resected stage II-IIIB EGFR-mutated NSCLC, while also demonstrating a favorable safety profile.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment